Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study

Data regarding protection against mortality and severe complications after Omicron BA.2 infection with CoronaVac and BNT162b2 vaccines remains limited. We conducted a case-control study to evaluate the risk of severe complications and mortality following 1-3 doses of CoronaVac and BNT162b2 using ele...

Full description

Saved in:
Bibliographic Details
Published in:Emerging microbes & infections 2022-12, Vol.11 (1), p.2304-2314
Main Authors: Yan, Vincent Ka Chun, Wan, Eric Yuk Fai, Ye, Xuxiao, Mok, Anna Hoi Ying, Lai, Francisco Tsz Tsun, Chui, Celine Sze Ling, Li, Xue, Wong, Carlos King Ho, Li, Philip Hei, Ma, Tiantian, Qin, Simon, Wong, Vincent Kai Chung, Tsang, Tat Chi, Tsui, Sik Hon, Chui, William Chun Ming, Cowling, Benjamin John, Leung, Gabriel Matthew, Lau, Chak Sing, Wong, Ian Chi Kei, Chan, Esther Wai Yin
Format: Article
Language:English
Subjects:
BNT162b2
CoronaVac
Coronaviruses
COVID-19
COVID-19 vaccines
Immunization
Mortality
Omicron BA.2
Severe acute respiratory syndrome coronavirus 2
Vaccine effectiveness
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data regarding protection against mortality and severe complications after Omicron BA.2 infection with CoronaVac and BNT162b2 vaccines remains limited. We conducted a case-control study to evaluate the risk of severe complications and mortality following 1-3 doses of CoronaVac and BNT162b2 using electronic health records database. Cases were adults with their first COVID-19-related mortality or severe complications between 1 January and 31 March 2022, matched with up-to 10 controls by age, sex, index date, and Charlson Comorbidity Index. Vaccine effectiveness against COVID-19-related mortality and severe complications by type and number of doses was estimated using conditional logistic regression adjusted for comorbidities and medications. Vaccine effectiveness (95% CI) against COVID-19-related mortality after two doses of BNT162b2 and CoronaVac were 90.7% (88.6-92.3) and 74.8% (72.5-76.9) in those aged ≥65, 87.6% (81.4-91.8) and 80.7% (72.8-86.3) in those aged 50-64, 86.6% (71.0-93.8) and 82.7% (56.5-93.1) in those aged 18-50. Vaccine effectiveness against severe complications after two doses of BNT162b2 and CoronaVac were 82.1% (74.6-87.3) and 58.9% (50.3-66.1) in those aged ≥65, 83.0% (69.6-90.5) and 67.1% (47.1-79.6) in those aged 50-64, 78.3% (60.8-88.0) and 77.8% (49.6-90.2) in those aged 18-50. Further risk reduction with the third dose was observed especially in those aged ≥65 years, with vaccine effectiveness of 98.0% (96.5-98.9) for BNT162b2 and 95.5% (93.7-96.8) for CoronaVac against mortality, 90.8% (83.4-94.9) and 88.0% (80.8-92.5) against severe complications. Both CoronaVac and BNT162b2 vaccination were effective against COVID-19-related mortality and severe complications amidst the Omicron BA.2 pandemic, and risks decreased further with the third dose.
ISSN:2222-1751
2222-1751
DOI:10.1080/22221751.2022.2114854